Pillar Biosciences aims to "Make precision medicine the first option for every patient" by developing and manufacturing targeted next-generation sequencing (NGS)-based assays and software for today’s high-throughput specialty NGS laboratories.
Through our SLIMamp technology (a multiplex overlapping PCR chemistry) Pillar offers a streamlined, robust and economical workflow with high mapping and on-target metrics.
In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly.
For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%.
Through our SLIMamp technology (a multiplex overlapping PCR chemistry) Pillar offers a streamlined, robust and economical workflow with high mapping and on-target metrics.
In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly.
For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%.
Location: United States, Massachusetts, Natick
Employees: 51-200
Total raised: $34.5M
Founded date: 2014
Founders name: Gang Song
Investors 1
| Date | Name | Website |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.05.2025 | - | $34.5M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Gang | Song | Chairman o... | linkedin.c... | - | - |
Mentions in press and media 4
| Date | Title | Description |
| 13.11.2025 | Clear Labs Unveils Automated Workflow Featuring Pillar Biosciences' SLIMamp® Technology at AMP 2025 | Clear Labs announced a new automated workflow featuring Pillar Biosciences' SLIMamp® chemistry on the Clear Dx™ platform, debuting at the AMP Annual Meeting. The collaboration expands Clear Labs' automation technology into oncology, enablin... |
| 29.05.2025 | Pillar Biosciences Secures $34.5 Million to Propel Decision Medicine Forward | Pillar Biosciences is on the rise. The Natik, Massachusetts-based company has secured $34.5 million in funding. This infusion comes from a mix of strategic investors, including Illumina and Soleus Capital. The goal? To enhance their Decisio... |
| 27.05.2025 | Pillar Biosciences Raises $34.5M in Funding | Pillar Biosciences, a Natik, MA-based decision medicine company, raised $34.5M in funding. Backers included Illumina, Soleus Capital and existing investors. The company intends to use the funds to advance its commercial activities including... |
| - | Pillar Biosciences | “Achieve robust, accurate genomic results with minimal turn-around time with Pillar's productivity-focused suite of NGS panels and software.” |